Ann Walker, APRN
Nurse Practitioner · Lincoln, NENPI 1437451598
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 48.2% of the total. 2025 is the largest year on record at $2,071, more than ten times the $28 reported in 2021. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $37.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- Jazz Pharmaceuticals Inc.$840
- Regeneron Healthcare Solutions, Inc.$339
- Harmony Biosciences LLC$327
- Grifols USA, LLC$213
- Sanofi-aventis U.S. LLC$172
- plus $928 from 19 others
What the payments were for
- Travel & lodging$1,72932%
- Food & beverage$2,75451%
- Education$96418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 29 | $2,627 |
| Jazz Pharmaceuticals Inc. | 29 | $840 |
| Regeneron Healthcare Solutions, Inc. | 11 | $339 |
| Harmony Biosciences LLC | 19 | $327 |
| Grifols USA, LLC | 9 | $213 |
| Sanofi-aventis U.S. LLC | 2 | $172 |
| Astellas Pharma US Inc | 4 | $163 |
| Boehringer Ingelheim | 7 | $111 |
| Sanofi | 5 | $76 |
| United Therapeutics Corporation | 2 | $75 |
| Amgen | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Insmed, Inc. | 4 | $67 |
| GSK | 2 | $36 |
| 3b Medical, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Philips North America LLC | 1 | $29 |
| AbbVie | 2 | $28 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| AstraZeneca | 2 | $27 |
| Verona Pharma, Inc. | 1 | $19 |
| Hospira, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,447 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 27 | $573,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 303 | $222,862 |
| WakixPitolisant Hcl | 11 | $167,653 |
| Dupixent PenDupilumab | 17 | $75,090 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $45,484 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 86 | $43,591 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $25,233 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $21,228 |
| Spiriva RespimatTiotropium Bromide | 29 | $16,074 |
| SunosiSolriamfetol Hcl | 18 | $15,329 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $14,950 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 22 | $13,042 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $12,209 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $11,318 |
| Spiriva HandihalerTiotropium Bromide | 14 | $9,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $36 | $269,323401 claims |
| Harmony Biosciences LLCWakix | $327 | $167,65311 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $27 | $73,476106 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $111 | $70,983133 claims |
| Axsome Therapeutics, Inc.Sunosi | $28 | $15,32918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Lincoln
- Lisa OstendorfLincoln$22K
- Jenna BeideckLincoln$9K
- Denise SpeichLincoln$5K
- Lindy VakocLincoln$5K
- Janice CunninghamLincoln$5K
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.